EGFR and neoplasm: Similarly, molecular mechanisms and tumor characteristics such as the overexpression of oncogenes (e.g., MDM285), EGFR mutations and associated changes in the TME86, or tumor hypoxia87 can also be predictive of the response to immunotherapy.